BASEL, Switzerland and
IRVINE, Calif., Nov. 5, 2019 /PRNewswire/ --
Quote from Alberto Santagostino, SVP Head of Cell & Gene
Technologies, Lonza Pharma & Biotech:
"The
Lonza-Cryoport collaboration is an enabling part of a wider goal
for Lonza to create a network of strategic partnerships and
capabilities that enable seamless vein-to-vein delivery of cell and
gene therapies for its customers and their patients. There is
no doubt that this partnership enables us to provide a
best-in-class solution to cell and gene therapy companies for
manufacturing and supply chain services, allowing us to provide a
fully integrated solution that reduces risk and increases
transparency."
Quote from Jerrell Shelton,
CEO, Cryoport:
"Clinical trial activity in the cell and gene
therapy sector is rapidly growing as biopharmaceutical companies
discover new ways to harness regenerative therapies and combat
illnesses. As more and more of these therapies approach
commercialization, there is strengthening demand for reliable,
integrated outsourced manufacturing and distribution
solutions. Our partnership agreement with Lonza, an
internationally-renowned supplier to the pharma and biotech
markets, will improve effectiveness, efficiency and safety
throughout the cell and gene therapy manufacturing process by
integrating our temperature-controlled supply chain solutions with
Lonza's manufacturing services."
Lonza (SWX: LONN) and Cryoport, Inc. (NASDAQ: CYRX)
("Cryoport"), announced today their partnership in the cell
and gene therapy field and across Lonza's 'vein-to-vein' delivery
network. As a part of this commitment, Lonza announced Cryoport as
its preferred partner in the transport and delivery of patient
tissues on a global basis, with the continued goal of seamless
service for Lonza's customers and their patients. Lonza and
Cryoport will work to remove the supply chain hurdles faced by
developers of personalized therapeutics -- including autologous
therapies, matched-allogeneic therapies, and personalized cancer
vaccines -- as they prepare for the commercial launch of their
respective therapies.
Lonza's network of cell and gene therapy facilities spans the
US, Europe and Asia and serves both clinical and commercial
customers globally. Cryoport currently supports over 413
clinical trials and 3 commercial therapies in the regenerative
medicine space and operates in over 100 countries around the world.
Integrating Cryoport's logistics and bioservices solutions
with Lonza's manufacturing services and expertise will ensure a
trusted and seamless supply chain and drive efficiencies in
delivering innovative medicines to patients.
The goal of the partnership is to provide fully integrated
solutions including, but not limited to, co-location of
manufacturing, bioservices and distribution facilities to improve
and enhance responsiveness and optimized product workflow,
automated data management providing integrated data entry, and
process optimization that reduces risk, increases transparency and
improves certainty.
Cryoport's logistics system aims to provide Lonza's clients with
reliable and comprehensive delivery solutions through its advanced
technologies, Global Supply Chain Network and dedicated scientists,
technicians and supporting teams of professionals. Beyond
Cryoport's proprietary Cryoport Express® Shippers, this partnership
incorporates Cryoport's Cryoportal® Logistics Management Platform
and SmartPak II™ Condition Monitoring System, which brings to the
market an integrated IT solution that provides risk mitigation and
Cryoport's unique Chain of Compliance™ for regulatory
solutions.
About Lonza
Lonza is an integrated solutions provider
that creates value along the Healthcare Continuum®.
Through our Pharma Biotech & Nutrition segment and our
Specialty Ingredients segment businesses, we harness science and
technology to serve markets along this continuum. We focus on
creating a healthy environment, promoting a healthier lifestyle and
preventing illness through consumers' preventive healthcare, as
well as improving patient healthcare by supporting our customers to
deliver innovative medicines that help treat or even cure severe
diseases.
Patients and consumers benefit from our ability to transfer our
pharma know-how to the healthcare, hygiene and fast-moving consumer
goods environment and to the preservation and protection of the
world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a
well-respected global company with more than 100 sites and offices
and approximately 15,500 full-time employees worldwide at the end
of 2018. The company generated sales of CHF
5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found
at www.lonza.com.
About Cryoport
Cryoport, Inc. (Nasdaq: CYRX) is the
world's premier provider of temperature-controlled supply
chain solutions for the life sciences industry, serving the
Biopharma, Human Reproductive, and Animal Health markets. Our
mission is to support life and health on earth by providing
reliable and comprehensive solutions for the life sciences through
our advanced technologies, Global Supply Chain Network and
dedicated scientists, technicians and supporting team of
professionals. Through purpose-built proprietary packaging;
information technology; smart, sustainable cold chain logistics;
and biostorage/biobanking services, Cryoport helps its customers
advance life sciences research, support life-saving advanced
therapies and deliver vaccines, protein producing materials, and
IVF treatments in over 100 countries around the world. For more
information, visit www.cryoport.com or follow @cryoport on Twitter
at www.twitter.com/cryoport for live updates.
Additional Information and Disclaimer (Lonza)
Lonza
Group Ltd has its headquarters in Basel,
Switzerland, and is listed on the SIX Swiss Exchange. It has
a secondary listing on the Singapore Exchange Securities Trading
Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's
continuing listing requirements but remains subject to Rules 217
and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute
forward-looking statements. These statements are based on current
expectations and estimates of Lonza Group Ltd, although Lonza Group
Ltd can give no assurance that these expectations and estimates
will be achieved. Investors are cautioned that all forward-looking
statements involve risks and uncertainty and are qualified in their
entirety. The actual results may differ materially in the future
from the forward-looking statements included in this news release
due to various factors. Furthermore, except as otherwise required
by law, Lonza Group Ltd disclaims any intention or obligation to
update the statements contained in this news release.
Forward Looking Statements (Cryoport)
Statements in
this news release which are not purely historical, including
statements regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the Company's SEC reports including,
but not limited to, the Company's 10-K for the year ended
December 31, 2018 filed with the SEC.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lonza-partners-with-cryoport-and-strengthens-its-vein-to-vein-delivery-network-in-cell--gene-therapy-300950920.html
SOURCE Cryoport, Inc.